Close Menu

Salk Institute

In more than a dozen new papers, ENCODE researchers reported on analyses of the human and mouse genomes, using new data types and additional tissues.

In Nature this week: catalog of changes associated with gene knockouts in yeast, simultaneous profiling of three-dimensional genome structure and DNA methylation in single cells, and more.

The team tested the system in living mice with progeria, inserting a normal copy of the LMNA gene into the animals to diminish features of the disease.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

In Genome Biology this week: catalog of curated human genes and transcripts; potential biomarkers for aging; and more.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.

And Settled

Science reports that the Salk Institute has settled the third of its three gender discrimination lawsuits.

Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.